公司资料
SCYNEXIS 股价、新闻与催化剂
- 股票代码:
- SCYX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
5.09 USD (-1.74%)
收盘价
最后更新: 2026年8月17日
50.6M USD
市值
股价为何变动
As of Aug 17, 2026, SCYX closed down 1.74% at $5.09. No new same-company headline was identified in the current news window.
公司概览
Metabolic Kidney-Disease Lead Program
SCYNEXIS is developing SCY-770, an orally administered, selective direct activator of AMPK acquired as PXL-770. The program is being advanced for autosomal dominant polycystic kidney disease, where AMPK activation may address multiple drivers of disease progression.
Antifungal Franchise
SCY-247 is the company's second-generation fungerp antifungal. It is being developed in oral and intravenous formulations for patients with serious fungal infections, including those with limited treatment options.
Small-Molecule Development Model
The company combines internally developed anti-infective expertise with acquired clinical assets, concentrating resources on differentiated small molecules with potential applications in both rare disease and hospital-based care.
未来催化剂
- Topline Phase 1 data for SCY-770 in the third quarter of 2026.
- Topline Phase 1 data for intravenous SCY-247 in the third quarter of 2026.
- Initiation of a Phase 2 proof-of-concept study of SCY-770 in ADPKD in the fourth quarter of 2026.
- Early efficacy data from the SCY-770 Phase 2 study in the second half of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。